PD-1/PD-L1 antibodies can lead to impressive antitumor responses by releasing the PD-1/PD-L1-mediated constraint of the immune system, and this activity has therefore become a highly promising treatment strategy for most types of cancers, especially lung cancer. Here, CD274 is linked to lung carcinoma.